CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
APC/C
CDC27
PD-L1
T-cell lymphoblastic lymphoma
cell cycle
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
01
2020
accepted:
18
03
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
T-lymphoblastic lymphoma (T-LBL) is a rare hematological malignancy with highly aggressive, unique clinical manifestations, and poor prognosis. Cell division cycle 27 (CDC27) was previously reported to be a significant subunit of the anaphase-promoting complex/cyclosome. However, the specific functions and relevant mechanisms of CDC27 in T-LBL remain unknown. Through immunohistochemistry staining, we identified that CDC27 was overexpressed in T-LBL tissues and related to tumor progression and poor survival. Functional experiments demonstrated that CDC27 promoted proliferation
Identifiants
pubmed: 32391258
doi: 10.3389/fonc.2020.00488
pmc: PMC7190811
doi:
Types de publication
Journal Article
Langues
eng
Pagination
488Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 Song, Song, Li, Song, Wen, Li, Xia and Zhang.
Références
J Immunother Cancer. 2018 Dec 27;6(1):159
pubmed: 30591082
Oncogene. 2010 Sep 23;29(38):5265-73
pubmed: 20639904
Haematologica. 2020 Mar;105(3):e107-e110
pubmed: 31413085
Nat Cell Biol. 1999 Jun;1(2):E47-53
pubmed: 10559897
Oncol Rep. 2012 Aug;28(2):615-21
pubmed: 22614805
Mol Cancer. 2018 Apr 12;17(1):81
pubmed: 29650000
Oncogene. 2005 Jan 6;24(1):1-10
pubmed: 15637585
Blood. 2016 Apr 14;127(15):1863-9
pubmed: 26747249
Nat Rev Mol Cell Biol. 2006 Sep;7(9):644-56
pubmed: 16896351
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Science. 2016 Jul 22;353(6297):399-403
pubmed: 27463676
BMC Genomics. 2018 Jul 16;19(1):538
pubmed: 30012096
Front Immunol. 2019 Jun 14;10:1337
pubmed: 31258527
Nat Commun. 2019 Sep 16;10(1):4209
pubmed: 31527657
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
J Cancer. 2017 Aug 21;8(13):2626-2635
pubmed: 28900500
Cell Physiol Biochem. 2018;50(2):501-511
pubmed: 30308498
J Surg Oncol. 2012 Sep 15;106(4):423-30
pubmed: 22488197
Science. 1999 May 21;284(5418):1351-4
pubmed: 10334988
Haematologica. 2019 Nov 28;:
pubmed: 31780634
Oncologist. 2019 Nov;24(11):e1123-e1131
pubmed: 30952822
Immunotherapy. 2019 Apr;11(6):515-529
pubmed: 30860441
Front Oncol. 2012 Jan 09;1:60
pubmed: 22655255
Cancer Res Treat. 2019 Apr;51(2):611-622
pubmed: 30025443
Oncotarget. 2017 Jan 24;8(4):6304-6318
pubmed: 27974673
Br J Haematol. 2018 May;181(3):406-410
pubmed: 28294301
Cancer Manag Res. 2019 Jul 10;11:6397-6410
pubmed: 31372044
Cancer Cell. 2011 Oct 18;20(4):487-99
pubmed: 22014574
J Biol Chem. 2011 Mar 25;286(12):10041-50
pubmed: 21209074
J Biomed Sci. 2019 Dec 5;26(1):96
pubmed: 31801525
J Hematol Oncol. 2012 Apr 04;5:15
pubmed: 22475564
Oncogene. 2020 Feb;39(6):1273-1289
pubmed: 31636387
Cells. 2019 Aug 01;8(8):
pubmed: 31374957
Cell Death Dis. 2016 Jan 28;7:e2074
pubmed: 26821069
Sci Rep. 2019 Sep 30;9(1):13995
pubmed: 31570735
Pharmacol Ther. 2018 Jun;186:138-151
pubmed: 29360538
Am J Clin Pathol. 2015 Sep;144(3):411-22
pubmed: 26276771
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
pubmed: 3893381
J Transl Med. 2013 Jun 10;11:142
pubmed: 23758705
Front Oncol. 2019 Aug 27;9:773
pubmed: 31552163
Sci Rep. 2018 Jan 18;8(1):1088
pubmed: 29348421
iScience. 2018 Nov 30;9:258-277
pubmed: 30439581
APMIS. 2013 Oct;121(10):945-53
pubmed: 23755904
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Genes Chromosomes Cancer. 2020 Mar;59(3):189-202
pubmed: 31652364
J Cell Biochem. 2020 Feb;121(2):1855-1869
pubmed: 31633227